| abstract |
The present invention a) a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof; b) comprising a therapeutically effective amount of valsartan or a pharmaceutically acceptable salt thereof, In pH 4.5, in vitro dissolution of component a) of 80% or less after 10 minutes, 98% or less after 20 minutes, and dissolution of component b) of 25% or more after 30 minutes and 40% or more after 60 minutes It relates to pharmaceutical oral fixed dose combinations that exhibit properties. |